1 day Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance MarketWatch

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of tougher times ahead.